AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER CELL THERAPY OF EPSTEIN-BARR VIRUS-POSITIVE AND -NEGATIVE LYMPHOPROLIFERATIVE DISORDERS ARISING IN ORGAN TRANSPLANT RECIPIENTS1
Michael A. Nalesnik(Western Pennsylvania Hospital), Thomas E. Starzl(University of Pittsburgh Medical Center), Hiro Furukawa(Cold Spring Harbor Laboratory), Adriana Zeevi(University of Pittsburgh), John J. Fung(University of Pittsburgh), George Klein, Si Pham(University of Pittsburgh Medical Center), Abdul S. Rao(University of Pittsburgh), H. Albin Gritsch(University of Pittsburgh Medical Center), Theresa L. Whiteside(UPMC Hillman Cancer Center), Elaine Elder(University of Pittsburgh Medical Center)
Cited by 109
Related Papers
Banff Schema for Grading Liver Allograft Rejection: An International Consensus Document
|Hepatology|1997|1.3k
REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY
|The Lancet|1984|1.3k
Production of α1,3-Galactosyltransferase-Deficient Pigs
|Science|2003|1.1k
Evolution of Liver Transplantation
|Hepatology|1982|887
Clinical Pharmacokinetics of Tacrolimus
|Clinical Pharmacokinetics|1995|802